Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)

被引：0

作者：

Hiroshi Nomoto

Chiho Oba-Yamamoto

Yuka Takahashi

Jun Takeuchi

So Nagai

Hiroki Yokoyama

Shinji Taneda

Yoshio Kurihara

Shin Aoki

Hiraku Kameda

Kyu Yong Cho

Akinobu Nakamura

Tatsuya Atsumi

Hideaki Miyoshi

机构：

[1] Hokkaido University,Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine

[2] Sapporo Diabetes and Thyroid Clinic,Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center

[3] NTT East Corporation,Department of Internal Medicine

[4] Jiyugaoka Medical Clinic,Diabetes Center

[5] Manda Memorial Hospital,Clinical Research and Medical Innovation Center

[6] Kurihara Clinic,Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine

[7] Aoki Clinic,undefined

[8] Hokkaido University Hospital,undefined

[9] Hokkaido University,undefined

来源：

Diabetes Therapy | 2021年 / 12卷

关键词：

Glucagon-like peptide-1 receptor agonist; Treatment satisfaction; Type 2 diabetes mellitus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：955 / 964

页数：9

共 31 条

[1] Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
Nomoto, Hiroshi
Oba-Yamamoto, Chiho
Takahashi, Yuka
Takeuchi, Jun
Nagai, So
Yokoyama, Hiroki
Taneda, Shinji
Kurihara, Yoshio
Aoki, Shin
Kameda, Hiraku
Cho, Kyu Yong
Nakamura, Akinobu
Atsumi, Tatsuya
Miyoshi, Hideaki
[J]. DIABETES THERAPY, 2021, 12 (03) : 955 - 964
[2] Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Takahashi, Yuka
Nomoto, Hiroshi
Yokoyama, Hiroki
Takano, Yoshinari
Nagai, So
Tsuzuki, Atsushi
Cho, Kyu Yong
Miya, Aika
Kameda, Hiraku
Takeuchi, Jun
Taneda, Shinji
Kurihara, Yoshio
Atsumi, Tatsuya
Nakamura, Akinobu
Miyoshi, Hideaki
[J]. DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1503 - 1511
[3] Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
Nomoto, Hiroshi
Furusawa, Sho
Nakamura, Akinobu
Takeuchi, Jun
Nagai, So
Yokoyama, Hiroki
Sakuma, Ichiro
Taneda, Shinji
Kurihara, Yoshio
Aoki, Shin
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Atsumi, Tatsuya
Miyoshi, Hideaki
[J]. BMJ OPEN, 2022, 12 (05):
[4] Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)
Furusawa, Sho
Nomoto, Hiroshi
Yokoyama, Hiroki
Suzuki, Yuka
Tsuzuki, Atsushi
Takahashi, Kiyohiko
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Takeuchi, Jun
Nagai, So
Taneda, Shinji
Kurihara, Yoshio
Nakamura, Akinobu
Atsumi, Tatsuya
[J]. DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 961 - 970
[5] GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes-Randomized, Parallel-Group, Multicenter, Open-Label Trial
Kimura, Tomohiko
Katakura, Yukino
Shimoda, Masashi
Kawasaki, Fumiko
Yamabe, Mizuho
Tatsumi, Fuminori
Matsuki, Michihiro
Iwamoto, Yuichiro
Anno, Takatoshi
Fushimi, Yoshiro
Kamei, Shinji
Kimura, Yukiko
Sanada, Junpei
Hirata, Yurie
Nakanishi, Shuhei
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
[J]. DIABETES, 2023, 72
[6] Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
Kameda, Reina
Nomoto, Hiroshi
Cho, Kyu Yong
Kawata, Shinichiro
Omori, Kazuno
Takeuchi, Jun
Nagai, So
Kurihara, Yoshio
Aoki, Shin
Nakamura, Akinobu
Atsumi, Tatsuya
Miyoshi, Hideaki
[J]. BMJ OPEN, 2020, 10 (02):
[7] Transfer of patients with type 1 diabetes from NPH insulin to insulin glargine as basal insulin: A multicenter, randomized, parallel-group open-label study
Bolli, Geremia B.
Songini, Marco
Trovati, Mariella
Del Prato, Stefano
Ghirlanba, Giovanni
Cordera, Renzo
Trevisan, Roberto
Riccardi, Gabriele
Noacco, Claudio
[J]. DIABETES, 2006, 55 : A479 - A479
[8] Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Shiraiwa, Toshihiko
Yasuda, Tetsuyuki
Okada, Yosuke
Torimoto, Keiichi
Umayahara, Yutaka
Kaneto, Hideaki
Osonoi, Takeshi
Yamamoto, Tsunehiko
Kuribayashi, Nobuichi
Maeda, Kazuhisa
Yokoyama, Hiroki
Kosugi, Keisuke
Ohtoshi, Kentaro
Hayashi, Isao
Sumitani, Satoru
Tsugawa, Mamiko
Ryomoto, Kayoko
Taki, Hideki
Nakamura, Tadashi
Kawashima, Satoshi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
[J]. CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[9] Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Naoto Katakami
Tomoya Mita
Hidenori Yoshii
Toshihiko Shiraiwa
Tetsuyuki Yasuda
Yosuke Okada
Keiichi Torimoto
Yutaka Umayahara
Hideaki Kaneto
Takeshi Osonoi
Tsunehiko Yamamoto
Nobuichi Kuribayashi
Kazuhisa Maeda
Hiroki Yokoyama
Keisuke Kosugi
Kentaro Ohtoshi
Isao Hayashi
Satoru Sumitani
Mamiko Tsugawa
Kayoko Ryomoto
Hideki Taki
Tadashi Nakamura
Satoshi Kawashima
Yasunori Sato
Hirotaka Watada
Iichiro Shimomura
[J]. Cardiovascular Diabetology, 19
[10] Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)
Kimura, Tomohiko
Katakura, Yukino
Shimoda, Masashi
Kawasaki, Fumiko
Yamabe, Mizuho
Tatsumi, Fuminori
Matsuki, Michihiro
Iwamoto, Yuichiro
Anno, Takatoshi
Fushimi, Yoshiro
Kamei, Shinji
Kimura, Yukiko
Nakanishi, Shuhei
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
[J]. DIABETES OBESITY & METABOLISM, 2023, : 3632 - 3647

← 1 2 3 4 →